Home > Insider Trading > Filing (0001181431-13-063433)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1361248	Tetralogic Pharmaceuticals Corp	TLOG	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
318154	Amgen Inc	One Amgen Center Drive Thousand Oaks CA 91320		No	No	Yes	No
1576997	Amgen Ventures Llc	One Amgen Center Drive Thousand Oaks CA 91320		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-12-17	448,767	$0.00	448,767	No	4	C	Direct
Common Stock	Acquisiton	2013-12-17	268,116	$0.00	268,116	No	4	C	Indirect	By Ventures
Common Stock	Acquisiton	2013-12-17	1,141	$6.40	269,257	No	4	X	Indirect	By Ventures
Common Stock	Acquisiton	2013-12-17	272,142	$7.00	541,399	No	4	P	Indirect	By Ventures

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	C	Indirect	By Ventures
No	4	X	Indirect	By Ventures
No	4	P	Indirect	By Ventures

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Convertible Notes	Disposition	2013-12-17	0	$0.00	448,767	$7.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2013-12-17	108,932	$0.00	108,932	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2013-12-17	117,361	$0.00	117,361	$0.00
Common Stock	Convertible Notes	Disposition	2013-12-17	0	$0.00	41,823	$7.00
Common Stock	Series C Convertible Preferred Stock Warrants (Right To Buy)	Disposition	2013-12-17	13,355	$0.00	13,355	$6.40

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	X	Indirect

Footnotes

Owned directly by Amgen Ventures LLC ("Ventures"), a wholly-owned subsidiary of Amgen Inc. ("Amgen"). Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein.
As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the "Registration Statement"), in connection with the Issuer's initial public offering (the "Offering"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock.
In accordance with the terms of the Warrant to Purchase Equity Securities, the warrant was net exercised and based on a fair market value of $7.00 per share, a net of 1,141 shares were acquired by Ventures.